138 related articles for article (PubMed ID: 24157285)
1. Global bionetworks and challenges in regulating autologous adult stem cells.
Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
Am J Med; 2013 Nov; 126(11):941-3. PubMed ID: 24157285
[No Abstract] [Full Text] [Related]
2. Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.
Lysaght T; Kerridge IH; Sipp D; Porter G; Capps BJ
J Bioeth Inq; 2017 Jun; 14(2):261-273. PubMed ID: 28247202
[TBL] [Abstract][Full Text] [Related]
3. Rejuvenating Regenerative Medicine Regulation.
Charo RA; Sipp D
N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
[No Abstract] [Full Text] [Related]
4. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
Turner L
Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
[TBL] [Abstract][Full Text] [Related]
5. FDA's claims over stem cells upheld.
Cyranoski D
Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
[No Abstract] [Full Text] [Related]
6. Global harmonization of regulatory requirements for premarket approval of autologous cell therapies.
Ward SM
Food Drug Law J; 2000; 55(2):225-43. PubMed ID: 12269366
[No Abstract] [Full Text] [Related]
7. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.
Munsie M; Pera M
Stem Cells Dev; 2014 Dec; 23 Suppl 1():34-8. PubMed ID: 25457959
[TBL] [Abstract][Full Text] [Related]
8. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
McLean AK; Stewart C; Kerridge I
J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
[TBL] [Abstract][Full Text] [Related]
9. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
10. FDA regulation of stem-cell-based therapies.
Halme DG; Kessler DA
N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899
[No Abstract] [Full Text] [Related]
11. New Japanese initiatives on stem cell therapies.
Konomi K; Tobita M; Kimura K; Sato D
Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
[TBL] [Abstract][Full Text] [Related]
12. Stem cells. U.S. regulation of stem cells as medical products.
Sipp D; Turner L
Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
[No Abstract] [Full Text] [Related]
13. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
Sipp D
Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
[TBL] [Abstract][Full Text] [Related]
14. The challenges of regulating stem cell-based products.
von Tigerstrom BJ
Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
[TBL] [Abstract][Full Text] [Related]
15. The deadly business of an unregulated global stem cell industry.
Lysaght T; Lipworth W; Hendl T; Kerridge I; Lee TL; Munsie M; Waldby C; Stewart C
J Med Ethics; 2017 Nov; 43(11):744-746. PubMed ID: 28356490
[TBL] [Abstract][Full Text] [Related]
16. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia.
Hendl T
Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149
[TBL] [Abstract][Full Text] [Related]
17. The dangers of unregulated stem-cell marketing.
Mohammadi D
Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714
[No Abstract] [Full Text] [Related]
18. Stem cell tourism and the role of health professional organizations.
Crozier GK; Thomsen K
Am J Bioeth; 2010 May; 10(5):36-8. PubMed ID: 20461646
[No Abstract] [Full Text] [Related]
19. Stem cells in Texas: Cowboy culture.
Cyranoski D
Nature; 2013 Feb; 494(7436):166-8. PubMed ID: 23407522
[No Abstract] [Full Text] [Related]
20. FDA should stand firm on stem-cell treatments.
Nature; 2016 Jul; 535(7610):7-8. PubMed ID: 27383946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
